Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 12319
Country/Region: Ethiopia
Year: 2015
Main Partner: Federal Police Commission - Ethiopia
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $1,729,405 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $90,000
Care: TB/HIV (HVTB) $182,383
Care: Pediatric Care and Support (PDCS) $20,000
Laboratory Infrastructure (HLAB) $30,000
Strategic Information (HVSI) $47,300
Health Systems Strengthening (OHSS) $50,000
Biomedical Prevention: Injection Safety (HMIN) $0
Testing: HIV Testing and Counseling (HVCT) $130,000
Sexual Prevention: Other Sexual Prevention (HVOP) $560,353
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $25,000
Treatment: Adult Treatment (HTXS) $569,369
Treatment: Pediatric Treatment (PDTX) $25,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 3,033
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 401
FN_THER Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period 2016 82
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 1,260
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 1,479
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 7,957
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 4,304
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 15,000
HTS_TST Sum of Aggregated Age/Sex <15 2016 2,739
HTS_TST Sum of Aggregated Age/Sex 15+ 2016 12,261
HTS_TST Sum of Aggregated Age/Sex disaggregates 2016 15,000
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2016 1
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2016 3
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 59
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 54
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 35
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 19
PMTCT_ARV Sum of New and Current disaggregates 2016 54
PMTCT_EID By infants who received a virologic test within 2 months of birth 2016 42
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2016 13
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 53
PMTCT_EID Sum of Infant Age disaggregates 2016 55
PMTCT_STAT By: Known positives at entry 2016 41
PMTCT_STAT By: Number of new positives identified 2016 18
PMTCT_STAT Number of new ANC and L&D clients 2016 1,082
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 1,028
PMTCT_STAT Sum of Positives Status disaggregates 2016 59
PP_PREV Age/sex: 20-24 Female 2016 1,470
PP_PREV Age/sex: 20-24 Male 2016 15,110
PP_PREV Age/sex: 25-49 Female 2016 1,200
PP_PREV Age/sex: 25-49 Male 2016 13,964
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2016 31,794
PP_PREV Sum of Age/Sex disaggregates 2016 31,794
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 3,033
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2016 2,973
TX_CURR Age/Sex: <1 Female 2016 5
TX_CURR Age/Sex: <1 Male 2016 7
TX_CURR Age/Sex: 1-4 Female 2016 20
TX_CURR Age/Sex: 1-4 Male 2016 23
TX_CURR Age/Sex: 5-14 Female 2016 41
TX_CURR Age/Sex: 5-14 Male 2016 39
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 2,725
TX_CURR Sum of age/sex disaggregates 2016 2,725
TX_NEW By Age/Sex: <1 Female 2016 2
TX_NEW By Age/Sex: <1 Male 2016 2
TX_NEW By Age/Sex: 1-4 Female 2016 4
TX_NEW By Age/Sex: 1-4 Male 2016 5
TX_NEW By Age/Sex: 10-14 Female 2016 3
TX_NEW By Age/Sex: 10-14 Male 2016 3
TX_NEW By Age/Sex: 15-19 Female 2016 4
TX_NEW By Age/Sex: 15-19 Male 2016 2
TX_NEW By Age/Sex: 20-24 Female 2016 38
TX_NEW By Age/Sex: 20-24 Male 2016 8
TX_NEW By Age/Sex: 25-49 Female 2016 188
TX_NEW By Age/Sex: 25-49 Male 2016 105
TX_NEW By Age/Sex: 5-9 Female 2016 5
TX_NEW By Age/Sex: 5-9 Male 2016 5
TX_NEW By Age/Sex: 50+ Female 2016 4
TX_NEW By Age/Sex: 50+ Male 2016 12
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 390
TX_NEW Sum of Age/Sex disaggregates 2016 390
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 273
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 276